Q3 2024 Phathom Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Phathom Pharmaceuticals Inc (PHAT) successfully launched VOQUEZNA for non-erosive GERD, achieving significant market penetration with over 143,000 prescriptions filled since launch.
- The company secured FDA approval for VOQUEZNA as a treatment for non-erosive GERD, expanding its addressable market to approximately 22 million U.S. adults.
- Phathom Pharmaceuticals Inc (PHAT) achieved over 80% commercial coverage for VOQUEZNA, with inclusion in major formularies like CVS Caremark, enhancing accessibility and affordability for patients.
- The company raised $130 million in equity financing, strengthening its balance sheet and signaling investor confidence in VOQUEZNA's market potential.
- VOQUEZNA has received positive feedback from physicians and patients, with increasing brand awareness and recognition in the marketplace, including multiple industry awards for innovation.
- Phathom Pharmaceuticals Inc (PHAT) reported a net loss of $67.9 million for the third quarter of 2024, reflecting ongoing financial challenges.
- The company is still early in its launch phase and has not provided financial guidance for projected revenues or earnings, indicating uncertainty in future financial performance.
- There is potential volatility in gross-to-net discount rates, which could impact financial results, especially with changes in health plans and deductibles in the upcoming quarters.
- The company faces risks related to regulatory exclusivity and is engaged in discussions with the FDA regarding the Orange Book listing, which could affect market exclusivity timelines.
- Despite progress, Phathom Pharmaceuticals Inc (PHAT) acknowledges that it is still in the early stages of growth for VOQUEZNA, with significant work needed to fully capitalize on its market opportunity.
Hello and welcome to the Fathom Pharmaceuticals third quarter, 2024 earnings results call (operator instructions) I would like to turn the conference over to Eric Sciorilli, Phatom's Head of Investor Relations. Please go ahead.
Thank you, operator. Hello, everyone and thank you for joining us this morning to discuss Phatom's third quarter, 2024 results. This morning's presentation will include remarks from Terry Curran, our President and CEO Martin Gilligan, our Chief Commercial Officer and Molly Henderson, our Chief Financial Officer, Osmi Bui, our Chief Operating Officer will also be joining the team during the Q&A portion of today's call. Just a couple of logistical items. Before we get started. Earlier this morning, we issued a press release detailing the results we will be discussing during the call. A copy of that press release can be found under the news releases section of our corporate website further, the recording of today's webcast can be found under the events and presentation section
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
